All results

15 results for randomized double blind placebo controlled study erlotinib or placebo patients

• CTD-TCNPC-301

  A prospective, randomized, double-blind, placebo controlled, multi-center therapeutic study for patients age 3 and older with confirmed diagnosis of Niemann…

  Ages

  3 Years - N/A

  Sexes

  All

• Soleno C602

  This is a multi-center, multi-period study with an open-label period followed by a double-blind, placebo-controlled, randomized withdrawal period evaluating…

  Ages

  4 Years - N/A

  Sexes

  All

• CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis

  This is a Phase 2, multicenter, multinational, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, pharmacokinetics (PK),…

  Ages

  40 Years - N/A

  Sexes

  All

• NIH AIM 2 - Low Dose Pioglitazone in NASH

  To determine the safety and efficacy of low-dose pioglitazone (15 mg per day) on liver histology in in patients with T2DM with biopsy-proven nonalcoholic…

  Ages

  21 Years - 75 Years

  Sexes

  All

• FASTEST Trial

  The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute…

  Ages

  18 Years - 80 Years

  Sexes

  All

• Adaptive COVID-19 Treatment Trial (ACTT)

  This study is an adaptive, randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of novel therapeutic agents in hospitalized…

  Ages

  18 Years - 99 Years

  Sexes

  All

• REPLENISH

  The purpose of this study is to demonstrate the efficacy and safety of secukinumab 300 milligram (mg) and 150 mg administered subcutaneously (s.c.) for 52…

  Ages

  50 Years - N/A

  Sexes

  All

• Vasomune AV001-004

  A Phase 2a, randomized, double-blind, placebo-controlled, multiple ascending dose study in patients who are hospitalized with presumed pneumonia requiring…

  Ages

  18 Years - N/A

  Sexes

  All

• GALACTIC-1

  This is a randomized, double-blind, placebo-controlled phase 2b trial in subjects with IPF (idiopathic pulmonary fibrosis) investigating the efficacy and…

  Ages

  40 Years - N/A

  Sexes

  All

• RECOVER VITAL

  This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community…

  Ages

  18 Years - N/A

  Sexes

  All